UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SANDOZ INC.,

Petitioner

v.

ELI LILLY AND COMPANY,

Patent Owner

U.S. Patent 7,772,209
Issue Date: Aug. 10, 2010
Title: Antifolate Combination Therapies

Inter Partes Review No. 2016-00318

PETITIONER SANDOZ INC.'S
CURRENT EXHIBIT LIST UNDER 37 C.F.R. § 42.63(e)

EXHIBIT LIST

Exhibit No.	Description	Referred To In The Petition As
Exhibit 1001:	U.S. Patent No. 7,772,209	"'209 patent"
Exhibit 1002:	File History of U.S. Patent Application No. 11/776,329, which issued as U.S. Patent No. 7,772,209 on August 10, 2010	"'209 file history"
Exhibit 1003:	Findings Of Fact And Conclusions Of Law Following Bench Trial August 19, 2013, in *Eli Lilly & Co. v. Teva Parenteral Medicines, Inc.*, Case No. 1:10-cv-1376, Dkt. 336 (S.D. Ind. March 31, 2014)	"Teva Decision"
Exhibit 1004:	Declaration of Ron D. Schiff, M.D., Ph.D.	"Schiff Decl."
Exhibit 1005:	U.S. Patent No. 5,217,974	"'974 patent"
Exhibit 1006:	C. Niyikiza, *et al.*, *MTA (LY231514): Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity*, Annals Oncology 9 (Suppl. 4): 125-140, Abstract 609P, (1998)	"Niyikiza I"
Exhibit 1007:	Hilary Calvert, *An Overview of Folate Metabolism: Features Relevant to the Action and Toxicities of Antifolate Anticancer Agents*, Seminars Oncology, 26: 3-10 (1999)	"Calvert"
Exhibit 1008:	*Textbook of Small Animal Medicine* (John K. Dunn ed. 1999)	"Animal Medicine"
Exhibit 1009:	Sidney Farber, *et al.*, *Temporary Remissions in acute leukemia in children produced by folic*	"Farber"

Exhibit No.	Description	Referred To In The Petition As
	acid antagonist, 4-aminopteroylglutamic acid (aminopterin), New Eng. J. Med., 238(23): 787-793	
Exhibit 1010:	Sarah L. Morgan, *et al*., *Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis*, Annals Internal Med., 121: 833-841 (1994)	"Morgan"
Exhibit 1011:	G.B. Grindey, *et al*., *Reversal of the toxicity but not the antitumor activity of Lometrexol by folic acid*, Am. Ass'n Cancer Res., 32: 324, Abstract 1921 (1991)	"Grindey"
Exhibit 1012:	Laurane G. Mendelsohn, *et al*., *Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887, in* Anticancer Drug Dev. Guide: Antifolate Drugs Cancer Therapy, (Ann L. Jackman, ed.) Ch. 12: 261-80 (1999)	"Mendelsohn"
Exhibit 1013	John F. Worzalla, *et al*., *Role of Folic Acid in Modulating the Toxicity and Efficacy of the Multitargeted Antifolate, LY231514*, Anticancer Res., 18: 3235-3240 (1998)	"Worzalla"
Exhibit 1014	L. Hammond, *et al*., *A Phase I and Pharmacokinetic (PK) Study of the Multitargeted Antifol (MTA) LY231514 with Folic Acid*, Proc. Am. Soc'y Clinical Oncology, 17: Abstract 866 (1998)	"Hammond II"
Exhibit 1015	L. Hammond, *et al*., *A phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA, LY231514) with folic acid (FA)*, Annals Oncology, 9: 129, Abstract 620P (1998)	"Hammond I"

Exhibit No.	Description	Referred To In The Petition As
Exhibit 1016	C. Niyikiza, *et al.*, *LY231514 (MTA): Relationship of vitamin metabolite profile to toxicity*, Proc. Am. Ass'n Cancer Res., 17: 558a, Abstract 2139 (1998)	"Niyikiza II"
Exhibit 1017	R. Thödtmann, *et al.*, *Preliminary Results of a Phase I Study with MTA (LY231415) in Combination with Cisplatin in Patients with Solid Tumors*, Seminars Oncology, 26 (2, Suppl. 6): 89-93 (1999)	"Thödtmann I"
Exhibit 1018	U.S. Patent No. 5,563,126	"'126 patent"
Exhibit 1019	Ernest Beutler & James K. Weick, *Blood and Neoplastic Disorders, in* Current Clinical Practice (Messerli, ed., 1987), Ch. 1: 291-302	"Beutler"
Exhibit 1020	Lars Brattström, *Vitamins as Homocysteine-Lowering Agents*, J. Nutrition, 126: 1276S-1280S (1996)	"Brattström"
Exhibit 1021	Chuan Shih, *et al.*, *LY231514, a Pyrrolo[2,3-d]pyrimidine-based Antifolate That Inhibits Multiple Folate-requiring Enzymes*, Cancer Res., 57, 1116- 1123 (1997)	"Shih"
Exhibit 1022	G. Robbin Westerhof, *et al.*, *Carrier- and Receptor-Mediated Transport of Folate Antagonists Targeting Folate-Dependent Enzymes: Correlates of Molecular-Structure and Biological Activity*, Am. Soc'y Pharmacology Experimental Therapeutics, 48: 459-471 (1995)	"Westerhof"
Exhibit 1023	F. G. Arsenyan, *et al.*, *Influence of Methylcobalamin on the Antineoplastic Activity of Methotrexate*, Pharmaceutical Chemistry J.,	"Arsenyan"

Exhibit No.	Description	Referred To In The Petition As
	12(10): 1299-1303 (1978)	
Exhibit 1024	File History of U.S. Patent Application No. 11/288,807, Abandoned	"'807 File History"
Exhibit 1025	U.S. Food & Drug Administration, *Approved Drug Products with Therapeutic Equivalents Evaluations* (30th ed. 2010)	"Orange Book Listing for Alimta®"
Exhibit 1026	Z.P. Sofyina, *et al.*, *Possibility to Increase the Antitumor Effect of Folic Acid Antagonist with the Help of Methylcobalamine Analogs*, Sci. Center Oncology 1:72-78 (1979)	"Sofyina"
Exhibit 1027	Victor Herbert, *The Role of Vitamin B_{12} and Folate in Carcinogenesis*, Advances Experimental Med. Biology, 206: 293-311 (1986)	"Herbert"
Exhibit 1028	Glenn Tisman, *et al.*, *Overcoming Colon Cancer Resistance to Hepatic Artery Infusional 5FUdR Chemotherapy with Folinic Acid*, Clinical Res., 33(2): 459A (1985)	"Tisman"
Exhibit 1029	J.D. Kinloch, *Maintenance Treatment of Pernicious Anaemia by Massive Parenteral Doses of Vitamin B_{12} at Intervals of Twelve Weeks*, Brit. Med. J., 1:99-100 (1960)	"Kinloch"
Exhibit 1030	D. Wray, *et al.*, *Recurrent Aphthae: Treatment with Vitamin B_{12}, Folic Acid, and Iron*, Brit. Med. J., 2:490-93 (1975)	"Wray"
Exhibit 1031	J. Tamura, *et al.*, *Immunomodulation by Vitamin B12: Augmentation of $CD8^+$ T Lymphocytes and Natural Killer (NK) Cell Activity in Vitamin B12-Deficient Patients by Methyl-B12 Treatment*, Clin. Experimental Immunology,	"Tamura"

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.